222 related articles for article (PubMed ID: 23990928)
1. Telomere length and the risk of cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations.
Burke LS; Hyland PL; Pfeiffer RM; Prescott J; Wheeler W; Mirabello L; Savage SA; Burdette L; Yeager M; Chanock S; De Vivo I; Tucker MA; Goldstein AM; Yang XR
PLoS One; 2013; 8(8):e71121. PubMed ID: 23990928
[TBL] [Abstract][Full Text] [Related]
2. Associations of 9p21 variants with cutaneous malignant melanoma, nevi, and pigmentation phenotypes in melanoma-prone families with and without CDKN2A mutations.
Yang XR; Liang X; Pfeiffer RM; Wheeler W; Maeder D; Burdette L; Yeager M; Chanock S; Tucker MA; Goldstein AM
Fam Cancer; 2010 Dec; 9(4):625-33. PubMed ID: 20574843
[TBL] [Abstract][Full Text] [Related]
3. Genetic variants in DNA repair genes and the risk of cutaneous malignant melanoma in melanoma-prone families with/without CDKN2A mutations.
Liang XS; Pfeiffer RM; Wheeler W; Maeder D; Burdette L; Yeager M; Chanock S; Tucker MA; Goldstein AM; Yang XR
Int J Cancer; 2012 May; 130(9):2062-6. PubMed ID: 21671477
[TBL] [Abstract][Full Text] [Related]
4. Identification of modifier genes for cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations.
Yang XR; Pfeiffer RM; Wheeler W; Yeager M; Chanock S; Tucker MA; Goldstein AM
Int J Cancer; 2009 Dec; 125(12):2912-7. PubMed ID: 19626699
[TBL] [Abstract][Full Text] [Related]
5. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
Goldstein AM; Struewing JP; Chidambaram A; Fraser MC; Tucker MA
J Natl Cancer Inst; 2000 Jun; 92(12):1006-10. PubMed ID: 10861313
[TBL] [Abstract][Full Text] [Related]
6. LINE-1 methylation in peripheral blood and the risk of melanoma in melanoma-prone families with and without CDKN2A mutations.
Hyland PL; Burke LS; Pfeiffer RM; Mirabello L; Tucker MA; Goldstein AM; Yang XR
Melanoma Res; 2013 Feb; 23(1):55-60. PubMed ID: 23222549
[TBL] [Abstract][Full Text] [Related]
7. Association of genetic variants in CDK6 and XRCC1 with the risk of dysplastic nevi in melanoma-prone families.
Liang X; Pfeiffer RM; Li WQ; Brossard M; Burke LS; Wheeler W; Calista D; Fargnoli MC; Ghiorzo P; Peris K; Bianchi-Scarra G; Chaudru V; Zelenika D; Maeder D; Burdette L; Yeager M; Chanock S; Landi MT; Demenais F; Tucker MA; Goldstein AM; Yang XR
J Invest Dermatol; 2014 Feb; 134(2):481-487. PubMed ID: 23892592
[TBL] [Abstract][Full Text] [Related]
8. POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families.
Potrony M; Puig-Butille JA; Ribera-Sola M; Iyer V; Robles-Espinoza CD; Aguilera P; Carrera C; Malvehy J; Badenas C; Landi MT; Adams DJ; Puig S
Br J Dermatol; 2019 Jul; 181(1):105-113. PubMed ID: 30451293
[TBL] [Abstract][Full Text] [Related]
9. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia.
Ruiz A; Puig S; Malvehy J; Lázaro C; Lynch M; Gimenez-Arnau AM; Puig L; Sánchez-Conejo J; Estivill X; Castel T
J Med Genet; 1999 Jun; 36(6):490-3. PubMed ID: 10874641
[TBL] [Abstract][Full Text] [Related]
10. Clinical and histologic characteristics of malignant melanoma in families with a germline mutation in CDKN2A.
van der Rhee JI; Krijnen P; Gruis NA; de Snoo FA; Vasen HFA; Putter H; Kukutsch NA; Bergman W
J Am Acad Dermatol; 2011 Aug; 65(2):281-288. PubMed ID: 21570156
[TBL] [Abstract][Full Text] [Related]
11. Lack of germline PALB2 mutations in melanoma-prone families with CDKN2A mutations and pancreatic cancer.
Yang XR; Jessop L; Myers T; Amundadottir L; Pfeiffer RM; Wheeler W; Pike KM; Yuenger J; Burdett L; Yeager M; Chanock SJ; Tucker MA; Goldstein AM
Fam Cancer; 2011 Sep; 10(3):545-8. PubMed ID: 21614589
[TBL] [Abstract][Full Text] [Related]
12. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants.
Puntervoll HE; Yang XR; Vetti HH; Bachmann IM; Avril MF; Benfodda M; Catricalà C; Dalle S; Duval-Modeste AB; Ghiorzo P; Grammatico P; Harland M; Hayward NK; Hu HH; Jouary T; Martin-Denavit T; Ozola A; Palmer JM; Pastorino L; Pjanova D; Soufir N; Steine SJ; Stratigos AJ; Thomas L; Tinat J; Tsao H; Veinalde R; Tucker MA; Bressac-de Paillerets B; Newton-Bishop JA; Goldstein AM; Akslen LA; Molven A
J Med Genet; 2013 Apr; 50(4):264-70. PubMed ID: 23384855
[TBL] [Abstract][Full Text] [Related]
13. CDKN2A variants in a population-based sample of Queensland families with melanoma.
Aitken J; Welch J; Duffy D; Milligan A; Green A; Martin N; Hayward N
J Natl Cancer Inst; 1999 Mar; 91(5):446-52. PubMed ID: 10070944
[TBL] [Abstract][Full Text] [Related]
14. Pediatric melanoma in melanoma-prone families.
Goldstein AM; Stidd KC; Yang XR; Fraser MC; Tucker MA
Cancer; 2018 Sep; 124(18):3715-3723. PubMed ID: 30207590
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of Germline BAP1, CDKN2A, and CDK4 Mutations in an Australian Population-Based Sample of Cutaneous Melanoma Cases.
Aoude LG; Gartside M; Johansson P; Palmer JM; Symmons J; Martin NG; Montgomery GW; Hayward NK
Twin Res Hum Genet; 2015 Apr; 18(2):126-33. PubMed ID: 25787093
[TBL] [Abstract][Full Text] [Related]
16. CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population.
Pjanova D; Engele L; Randerson-Moor JA; Harland M; Bishop DT; Newton Bishop JA; Taylor C; Debniak T; Lubinski J; Kleina R; Heisele O
Melanoma Res; 2007 Jun; 17(3):185-91. PubMed ID: 17505264
[TBL] [Abstract][Full Text] [Related]
17. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
[TBL] [Abstract][Full Text] [Related]
18. Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain.
Sargen MR; Calista D; Elder DE; Massi D; Chu EY; Potrony M; Pfeiffer RM; Carrera C; Aguilera P; Alos L; Puig S; Elenitsas R; Yang XR; Tucker MA; Landi MT; Goldstein AM
J Am Acad Dermatol; 2020 Sep; 83(3):860-869. PubMed ID: 32283231
[TBL] [Abstract][Full Text] [Related]
19. On the interplay of telomeres, nevi and the risk of melanoma.
Bodelon C; Pfeiffer RM; Bollati V; Debbache J; Calista D; Ghiorzo P; Fargnoli MC; Bianchi-Scarra G; Peris K; Hoxha M; Hutchinson A; Burdette L; Burke L; Fang S; Tucker MA; Goldstein AM; Lee JE; Wei Q; Savage SA; Yang XR; Amos C; Landi MT
PLoS One; 2012; 7(12):e52466. PubMed ID: 23300679
[TBL] [Abstract][Full Text] [Related]
20. BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.
Monnerat C; Chompret A; Kannengiesser C; Avril MF; Janin N; Spatz A; Guinebretière JM; Marian C; Barrois M; Boitier F; Lenoir GM; Bressac-de Paillerets B
Fam Cancer; 2007; 6(4):453-61. PubMed ID: 17624602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]